There are several therapeutics that target the PI3K–Akt pathway in clinical development for the treatment of cancer. These include dual PI3K–mTOR inhibitors, PI3K inhibitors, Akt inhibitors and mTOR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback